Unit
Cancer, Heterogeneity, Instability and Plasticity - CHIP (U830)
Thematic areas of research:
Image
To top
Unit
OLIVIER DELATTRE / FATIMA MECHTA-GRIGORIOU
Cancer, Heterogeneity, Instability and Plasticity - CHIP (U830)
The INSERM/Institut Curie U830 conducts both basic and applied research in the field of cancer biology. Located on the Paris site of Institut Curie, it strongly benefits from the outstanding scientific environment of the Institut Curie research center and from the proximity of the cancer hospital.
Teams
Key figures
76
publications in 2020
9
ongoing European projects in 2020
2
ongoing ERC in 2020
Key publications
All publications
-
Different Pigmentation Risk Loci for High-Risk Monosomy 3 and Low-Risk Disomy 3 Uveal MelanomasJNCI: Journal of the National Cancer Institute
-
-
-
-
-
News
All news
-
Response to chemotherapy: finally a biomarker for triple negative breast cancerIn triple negative breast cancer, how do we select those patients who will respond to chemotherapy with platinum salts? In Nature Communications, a team from Institut Curie makes an interesting proposal: to use the homologous recombination defect as a biomarker.25/04/2023 -
Institut Curie’s latest progress at the AACR Annual Meeting 2023From April 14 to 19, 2023, in Orlando, USA, the international scientific and medical community comes together for the annual meeting of the American Association for Cancer Research, an opportunity for scientists from Institut Curie to present their findings in various fields of cancer research.17/04/2023 -
A new factor in prognosis for metastatic uveal melanomaHow can we achieve a more accurate prognosis for patients after removal of liver metastases from uveal melanoma? By using a differentiating marker, namely circulating tumor DNA. This has just been shown by a study in one of the top surgery journals, Annals of Surgery, involving Institut Curie’s medical and research teams.31/03/2023 -
Institut Curie certified as Integrated cancer research site for the third timeFollowing a call for applications launched in April 2022, Institut Curie had its integrated cancer research site project certified by France’s Institut national du cancer (Inca). Its goal is to better understand tumor recurrences in order to better prevent, detect and treat them.20/02/2023 -
Dr. Olivier Delattre, winner of the Inserm 2022 Grand PrixDr. Olivier Delattre, director of the SIREDO center at Institut Curie and the Research Center’s Cancer, Heterogeneity, Instability and Plasticity Unit, was awarded the Inserm 2022 Grand Prix on December 6, 2022 at the Collège de France in a mark of recognition for the Inserm research director and oncopediatrician’s major discoveries in, and commitment to, pediatric cancer.08/12/2022 -
L’Institut Curie, catalyseur d’innovation avec 101 inventeurs à son actifEn cette journée mondiale de l’inventeur, l’Institut Curie salue ses 101 salariés inventeurs comptabilisés en 2022. Un chiffre impressionnant qui traduit l’engagement de l’Institut Curie à encourager l’innovation auprès de ses collaborateurs, ainsi que l’excellence et l’inventivité des travaux des chercheurs, médecins et soignants, au bénéfice des patients.08/11/2022
Scientific events
All scientific events
2 Jun
2023
Seminar
14h-15h
Mechanisms of Transcriptional Regulation in Drosophila & Mammalian Cells
Abstract
Transcription in higher eukaryotes is highly orchestrated at our ~20K mRNA encoding genes. The levels and cellular patterns of transcription of these genes respond to a spectrum of signals including those occurring in response to our normal program of development, in response to changes in nutrition and environment, and importantly, in response to infection and other disease states. Th
Transcription in higher eukaryotes is highly orchestrated at our ~20K mRNA encoding genes. The levels and cellular patterns of transcription of these genes respond to a spectrum of signals including those occurring in response to our normal program of development, in response to changes in nutrition and environment, and importantly, in response to infection and other disease states. Th
16 Jun
2022
Seminar
12h-13h
Using genomics to invesIgate radiaIon-related thyroid cancer following the Chernobyl accident in 1986
Following the Chernobyl nuclear power plant accident in Ukraine in 1986, increased childhood exposure to radioactive iodine (131I), which occurred primarily through consumption of contaminated food sources, has been consistently associated with increased risk of developing papillary thyroid carcinoma (PTC). In a landscape analysis of fresh-frozen tumor tissues from the Chernobyl Tissue B